GlassScriptPhysician profile
Gregorio J Guillen
NPI 1538252226
$8,393.97
in general payments reported to CMS, 2019-2025
41 companies · $993 in 2025
The $993 reported for 2025 was more than what 89% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $839 · 2021: $322 · 2022: $1,149 · 2023: $1,482 · 2024: $1,761 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $26.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.59 |
| Education | $26.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,031.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $823.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $752.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $735.63 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $692.50 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $625.11 | 2019-2025 | |
| Amgen INC. | $526.10 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $470.19 | 2019-2025 | |
| Pfizer INC. | $265.89 | 2019-2025 | |
| Lilly USA, LLC | $265.38 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $241.75 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $203.33 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $192.92 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $184.50 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $156.02 | 2019-2024 | Linzess |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregorio Guillen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.